First-line therapy with cabozantinib was superior to standard of care sunitinib with respect to progression-free survival and objective response rate for patients with intermediate- or poor-risk metastatic renal cell...
First-line therapy with cabozantinib was superior to standard of care sunitinib with respect to progression-free survival and objective response rate for patients with intermediate- or poor-risk metastatic renal cell...
...